NCT06162221 2026-03-09
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Phase 1/2 Recruiting
Revolution Medicines, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Sanofi
Northwell Health
Cantargia AB
University of California, San Diego
Noxopharm Limited
Merck Sharp & Dohme LLC
Accenture
Ohio State University Comprehensive Cancer Center
AHS Cancer Control Alberta
University of Alabama at Birmingham
Hellenic Oncology Research Group
University of New Mexico